Navigation Links
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Date:9/26/2007

phine-induced constipation, while maintaining substantial central analgesic effect. In addition, orally-administered NKTR-118 had a favorable safety and pharmacokinetic profile in an animal model.

About NKTR-118

NKTR-118 is an oral drug that combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. In preclinical studies, Nektar's PEGylation technology has been shown to prevent oral NKTR-118 from crossing the blood-brain barrier, an important potential advance for this and possibly many other small molecule therapies.

The antagonist NKTR-118 targets mu-opioid receptors within the enteric nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. NKTR-118 is currently in a second Phase 1 trial to evaluate the safety and tolerability of repeated dose administration.

According to IMS Health, more than 200 million prescriptions were written for opioids in 2006 in the United States, alone. Many studies indicate that a high percentage of patients receiving opioids are likely to experience significant constipation and other symptoms of OBD. Currently, there are no specific drugs approved that are indicated to treat OBD or OIC. Stool softeners or laxatives may be ineffective for many patients with OIC and they are often associated with side effects like diarrhea and cramping.

Data Presentations for NKTR-118

The NKTR-118 poster presentations from this week's American Academy of Pain Management's Annual Clinical Meeting in Las Vegas, Nevada from September 27-30, 2007 can be found on Nektar's website at http://www.nektar.com/wt/page/nktr118_media:

Poster #27: "Clinical Investigation
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
(Date:5/17/2013)... 17, 2013 Medical devices are any medical ... product. In light of their different mechanisms, actions and ... more complicated than drug trails due to their unique ... instead of evaluating both safety and efficacy (which is ... is the same as the SFDA) evaluate MDs for ...
(Date:5/17/2013)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today announced ... Global Healthcare Conference in New York . ... at 11 a.m. Eastern Time. To listen to the live ... Investor Relations section of the Company,s Web site at ... after the event. About Orexigen® Therapeutics Orexigen ...
Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Statistical Challenges in Medical Device Trail Evaluation 2
... SAN DIEGO, Dec. 21, 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ... President and Chief Executive Officer, will host a conference call ... Eastern Time (5:30 a.m. Pacific Time) to provide an update ... Food and Drug Administration (FDA) for the lorcaserin New Drug ...
... YORK, Dec. 21, 2010 Reportlinker.com announces that ... its catalogue: U.S. Preclinical ... http://www.reportlinker.com/p0350308/US-Preclinical-Animal-Imaging-Systems-Market.html This research ... Animal Imaging Systems Market since 2006. It examines ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA 2Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA 3
(Date:5/18/2013)... May 18, 2013 In a May ... Preventive Double Mastectomy After Discovering Cancer Gene,” Fox News ... procedure upon learning that she carried a gene that ... breast cancer and a 50 percent risk of ovarian ... up on May 16, 2013 with a blog post ...
(Date:5/18/2013)... FL (May 18, 2013) A ground-breaking advance ... care, according to research presented today at Digestive ... the minimal withdrawal time for colonoscopies and exploring ... During colonoscopy, doctors use a device called a ... for colorectal cancer allows a doctor to look ...
(Date:5/18/2013)... York, New York (PRWEB) May 18, 2013 ... Gynecare pelvic mesh products continue to move forward in ... Superior Court, Bernstein Liebhard LLP reports. According to a ... Conference in the Ethicon pelvic mesh litigation will be ... that 2,755 complaints have been filed in the proceeding ...
(Date:5/18/2013)... FRIDAY, May 17 (HealthDay News) -- It comes as little ... shows that college women are more likely to drink unhealthy ... men. Much of this difference is probably because ... basis is much lower for women than it is for ... there,s good reason for that difference. Women don,t metabolize alcohol ...
(Date:5/18/2013)... After working diligently for months and putting in ... the integration of the fitment specs for the redesigned 2012 ... stun the automobile market with its extraordinary features and unique ... as the latest entry in the size it up ... the year 2013. , Aptly suiting its name, 2012 ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2
... The Pain Relief Network (PRN) is calling on the ... join the organization,s recent filing of a Petition for ... Court on behalf of Dr. Sharon Johnston.In his first ... Office of National Drug Control Policy, Gil Kerlikowske said ...
... May 18 Carnival Corporation & plc (NYSE/LSE: CCL; ... approximately $0.05 per share, the majority of which will ... as a result of modifications to cruise itineraries for ... the U.S. Centers for Disease Control (CDC) recommendation against ...
... The National Autism Association (NAA) announced today it has ... Project Lifesaver Equipment through the organization,s FOUND Program. ... Sheriff,s Department will both receive grants for $6800 for ... autism at high risk for wandering. FOUND was developed ...
... Patients Taking Lialda(R) (mesalamine) or Pentasa(R) (mesalamine) for the ... in 2009PHILADELPHIA, May 18 Shire plc (LSE: SHP, ... company, is responding to the needs of patients who ... (GI) medications from Shire by expanding its Patient Assistant ...
... Chain Top 25 to Be Announced at EventBOSTON, May 18 ... firm focused on the global supply chain and its supporting ... Chain Executive Conference, to be held at The Phoenician Resort ... a keynote address from Michael Eisner, CEO of Walt Disney ...
... Airways remained clear and moist in studies, researcher says , , ... may help keep the airways of cystic fibrosis patients moist ... GS-9411, the spray prevents sodium from being absorbed too quickly, ... The quick absorption of sodium from the surface of the ...
Cached Medicine News:Health News:PRN Calls on Obama Lawyers to Stand Down in Their Drug War on Patients and Doctors 2Health News:Carnival Corporation & plc Reports Financial Impact of Itinerary Changes Responding to H1N1 Influenza Mexico Travel Advisory; Plans Rapid Return to Popular Mexican Ports 2Health News:National Autism Association Provides Funds to Law Enforcement Agencies in Staunton, Virginia and Summit County, Utah for Project Lifesaver Equipment 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 3Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 4Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 5Health News:AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference 2Health News:New Spray Could Benefit Cystic Fibrosis Patients 2
... Medline Has the Right Solution For Your ... clean and care tray features the latest ... this important infection control task. Designed by ... individual needs of each patient and caregiver. ...
... Kendall provides hospitals and alternate care ... tracheostomy care trays which offer the ... control. Designed with the guidance of ... trays provide exactly what is required ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions....
Medicine Products: